LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Kodu・Aktsiate loetelu・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Suletud

SektorTervishoid

64.67 -3.03

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

63.67

Max

67.39

Põhinäitajad
By Trading Economics
Sissetulek	-7.5M -190M
Müük	33M 154M
Kasumimarginaal	-123.403
Töötajad	834
EBITDA	-6.9M -180M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+58.35% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	4. aug 2026

Turustatistika
By TradingEconomics
Turukapital	361M 13B
Eelmine avamishind	67.7
Eelmine sulgemishind	64.67

Uudiste sentiment

By Acuity

50%

153 / 347 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

34.71 / 36.9 Toetus ja vastupanu

Bridgebio Pharma Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. mai 2026, 23:47 UTC

Market Talk

Gold Falls on Renewed Inflation Concerns -- Market Talk

10. mai 2026, 23:44 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Economic Strength -- Market Talk

10. mai 2026, 23:38 UTC

Market Talk

Oil Rises Amid Signs of Ongoing Middle East Tensions -- Market Talk

10. mai 2026, 23:14 UTC

Market Talk

Australia's Political Map Continues to Be Redrawn -- Market Talk

10. mai 2026, 22:22 UTC

Omandamised, ülevõtmised, äriostud

Elevra Lithium: Expects Deal to Close in 1Q FY27

10. mai 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Elevra Lithium: Expects to Received About $71 Million Before Fees, Taxes in Cash

10. mai 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Elevra Lithium Agrees to Sell Ewoyaa Lithium Project Stake to Zhejiang Huayou Cobalt

10. mai 2026, 10:21 UTC

Tulu

Saudi Aramco Profit Jumps Despite War Disrupting Shipping Routes -- WSJ

9. mai 2026, 06:05 UTC

Tulu

Our Innodata Stock Pick Smashed Earnings Expectations. Stay Long. -- Barrons.com

8. mai 2026, 23:55 UTC

Tulu

Review & Preview: Still Going Strong -- Barrons.com

8. mai 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. mai 2026, 20:49 UTC

Tulu

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8. mai 2026, 20:25 UTC

Tulu

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8. mai 2026, 19:43 UTC

Tulu

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8. mai 2026, 19:43 UTC

Tulu

Cencosud 1Q Net $115M

8. mai 2026, 19:20 UTC

Market Talk

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8. mai 2026, 19:18 UTC

Tulu

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8. mai 2026, 19:16 UTC

Tulu

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8. mai 2026, 19:08 UTC

Tulu

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8. mai 2026, 19:05 UTC

Tulu

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8. mai 2026, 19:02 UTC

Market Talk

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8. mai 2026, 18:51 UTC

Tulu

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8. mai 2026, 18:49 UTC

Tulu

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8. mai 2026, 18:41 UTC

Tulu

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8. mai 2026, 17:38 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8. mai 2026, 17:14 UTC

Tulu

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8. mai 2026, 17:04 UTC

Market Talk

Zcash Caps Off Parabolic Week -- Market Talk

8. mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8. mai 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

8. mai 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Bridgebio Pharma Inc Prognoos

Hinnasiht

By TipRanks

58.35% tõus

12 kuu keskmine prognoos

Keskmine 106.71 USD 58.35%

Kõrge 157 USD

Madal 81 USD

Põhineb 18 Wall Streeti analüütiku instrumendi Bridgebio Pharma Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

18 ratings

Osta

Hoia

Müü

Põhineb 18 analüütiku instrumendi Bridgebio Pharma Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

34.71 / 36.9Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

153 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.